Article
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Cancer research - 1 Jan 2006
Schittenhelm Marcus M, Shiraga Sharon, Schroeder Arin, Corbin Amie S, Griffith Diana, Lee Francis Y, Bokemeyer Carsten, Deininger Michael W N, Druker Brian J, Heinrich Michael C
Abstract excerpt
Activating mutations of the activation loop of KIT are associated with certain human neoplasms, including the majority of patients with systemic mast cell disorders, as well as cases of seminoma, acute myelogenous leukemia (AML), and gastrointestinal stromal tumors (GISTs). The small-molecule tyr...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.